Skip to content

Syngene: Can it keep its premium valuation, going forward?

Investment in biologics is expected to remain recurring as new opportunities are unfolding in the field of biologics for Syngene

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

en_USEnglish